By Colin Kellaher
Nurix Therapeutics has widened its collaboration with Sanofi, granting the French pharmaceutical company an exclusive license to an undisclosed program targeting a previously undruggable transcription factor for autoimmune diseases.
Nurix on Wednesday said it received a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount the San Francisco clinical-stage biopharmaceutical company has received to date under the pact to $105 million.
Nurix said the new collaboration target is a central regulator of the inflammation response and is distinct from the companies' existing STAT6 degrader program.
Nurix said it remains eligible for up to $465 million in development, regulatory and commercial milestone payments per licensed program under its work with Sanofi, as well as royalties on future sales.
Shares of Nurix were recently up 3.1% to $10.79 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 02, 2025 07:33 ET (11:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.